Financing Archives · BioBuzz

Loading …

Seraxis Announces Closing of $40M Series C Financing Round

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-75x75.jpg 75w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis.jpg 500w" data-src="https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis-75x75.jpg 75w, https://biobuzz.io/wp-content/uploads/2021/02/Seraxis.jpg 500w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : February 9, 2021February 9, 2021 Published by : BioBuzz Media

GERMANTOWN, Md., Feb. 9, 2021 /PRNewswire/ –Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes today announced the successful closing of a $40M Series C private financing round. The financing was [….]